Welcome to our dedicated page for Caredx news (Ticker: CDNA), a resource for investors and traders seeking the latest updates and insights on Caredx stock.
CareDx, Inc. reports developments in precision medicine for transplant patients and caregivers. The company’s updates center on non-invasive molecular testing for heart, kidney, and lung transplantation, including AlloSure, AlloMap, HeartCare, and related evidence generation for post-transplant surveillance, risk assessment, and longitudinal patient management.
CareDx news also covers operating and financial results for testing services and patient and digital solutions, product and platform launches such as VANTx clinical data analytics, clinical conference presentations, material agreements, and Nasdaq-related governance matters including inducement equity awards.
CareDx, Inc. (Nasdaq: CDNA) announced its acquisition of TransChart LLC, an electronic health record software provider for US transplant centers. The deal, expected to close in January 2021, will enhance CareDx's digital capabilities and expand its EMR coverage to over 90 centers. Both companies aim to improve transplant patient outcomes through data-driven solutions. The transaction emphasizes CareDx's commitment to delivering high-value healthcare solutions for transplant patients and integrating TransChart's offerings into its existing services.
CareDx presented new clinical data at the 21st Annual American Society of Transplant Surgeons Digital Winter Symposium, focusing on transplant patient care. The company sponsored two symposia featuring prominent clinical leaders discussing their experiences with AlloSure, including the ADMIRAL and MAPLE studies. Notable speakers included Dr. Jason Wellen and Dr. Sander Florman. There were three accepted abstracts highlighting CareDx solutions. CEO Reg Seeto expressed optimism about sharing important new data with the transplant community.
CareDx has announced a strategic partnership with IDbyDNA to develop AlloID, a metagenomic infectious disease testing platform tailored for transplant patients. This innovative solution aims to identify over 100 pathogens and drug resistance, enhancing care for immunocompromised organ transplant recipients. The collaboration combines AlloID with existing CareDx tools like AlloSure and AlloMap, striving for comprehensive, personalized care. The technology promises improved detection through next-generation sequencing, which is vital for managing infections in transplant patients.
CareDx has secured a two-year tender with the French National Blood Service, Établissement Français du Sang, to supply its AlloSeq HCT chimerism monitoring solution for stem cell transplant patients. This contract highlights CareDx's innovation in the field as the first next-generation sequencing (NGS) solution approved by EFS. The selection process was competitive, with AlloSeq HCT being chosen for its superior sensitivity and rapid under 24-hour turnaround time. CareDx aims to enhance transplant patient care across France through this partnership.
Summary not available.
CareDx, Inc. (Nasdaq: CDNA) announced a significant study published in Pediatric Transplantation that demonstrates the effectiveness of AlloSure in detecting allograft rejection in pediatric kidney transplant patients. The study, involving 67 patients tested from October 2017 to October 2019, shows that AlloSure offers a non-invasive and highly predictive method for early rejection detection, surpassing traditional indicators. This publication supports CareDx's commitment to improving long-term outcomes for young transplant recipients.
CareDx, a precision medicine company, will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference from December 1 to December 3, 2020. The company focuses on high-value healthcare solutions for transplant patients and their caregivers. A link to the fireside chat presentation will be available in the 'Investors' section of CareDx's website. Known for its genomics-based information services, CareDx is committed to enhancing patient care along the pre- and post-transplant journey.
CareDx, Inc. (Nasdaq: CDNA) announced a significant development regarding its AlloSure Heart test, which has received final reimbursement pricing of $2,753 from Palmetto MolDx. This donor-derived cell-free DNA test detects organ rejection in heart transplant patients and is covered by Medicare when paired with AlloMap Heart gene expression profiling. The combination, known as HeartCare, is a non-invasive solution aimed at enhancing patient management. CEO Reg Seeto emphasized that this milestone will improve heart transplant patient care accessibility.
CareDx, a leader in precision medicine for transplant patients, announced its participation in two virtual conferences. The Jefferies Virtual London Healthcare Conference is scheduled for November 17, 2020, at 10:50 AM EST, while the Canaccord Genuity Virtual MedTech & Diagnostics Forum is set for November 19, 2020, at 3:30 PM EST. Interested parties can access live webcasts on the company’s investor website. CareDx focuses on genomics-based solutions for transplant care, offering vital testing services and digital healthcare tools for patients and caregivers.
CareDx (Nasdaq: CDNA) announced a study published in Transplantation Direct indicating that AlloSure may effectively signal progression of BK virus (BKV) in transplant patients. The research utilized data from the Diagnosing Acute Rejection in Kidney Transplant Recipients (DART) study, revealing that AlloSure can distinguish asymptomatic BKV from BKV-associated nephropathy (BKVAN). This method could enhance patient care by reducing reliance on kidney biopsies, which have significant limitations. CareDx aims to expand the understanding of AlloSure to improve outcomes for transplant patients.